A heart attack, or myocardial infarction, happens when blood flow to the heart becomes blocked. Classic symptoms include chest pain, shortness of breath, and heightened anxiety, but some people may ...

Selatogrel is under clinical development by Idorsia Pharmaceutical and currently in Phase III for Myocardial Infarction. According to GlobalData, Phase III drugs for Myocardial Infarction have a 65% ...

BI-765845 is under clinical development by Boehringer Ingelheim International and currently in Phase II for Myocardial Infarction. According to GlobalData, Phase II drugs for Myocardial Infarction ...

Given changes in patient characteristics and treatments over time, a contemporary risk model for patients with acute myocardial infarction (MI) is needed. Data from 313 825 acute MI hospitalizations ...

Acute myocardial infarction (AMI) remains a leading cause of mortality and morbidity worldwide, accounting for approximately 40%–50% of sudden cardiac deaths (Rallidis et al., 2022). Although prompt ...

In the ABYSS (Assessment of Beta-Blocker Interruption 1 Year After an Uncomplicated Myocardial Infarction on Safety and Symptomatic Cardiac Events Requiring Hospitalization) trial, interruption of ...

Myocardial infarction (MI) is the leading cause of morbidity and mortality worldwide. Curcumin has been observed to significantly reduce pathological processes associated with MI. Its clinical ...

Despite a growing body of evidence that impaired clearance of apoptotic cells contributes to chronic autoimmune disease, how apoptotic cell engulfment influences cell death after acute myocardial ...